Skip to main content
Print

TAK-721 FDA Approval Status

Last updated by Judith Stewart, BPharm on Dec 16, 2020.

FDA Approved: No
Brand name: TAK-721
Generic name: budesonide
Dosage form: Oral Suspension
Company: Takeda Pharmaceutical Company Limited
Treatment for: Eosinophilic Esophagitis

TAK-721 (budesonide oral suspension) is a novel mucoadherent topically active oral viscous formulation of budesonide in development as a treatment for eosinophilic esophagitis (EoE).

Development timeline for TAK-721

DateArticle
Sep 20, 2023Takeda Announces FDA Acceptance of NDA Resubmission of TAK-721 (budesonide oral suspension) for the Short-Term Treatment of Eosinophilic Esophagitis (EoE)
Dec 21, 2021Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
Dec 15, 2020U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer